Women have Lower Risk of Nonalcoholic Fatty Liver Disease but Higher Risk of Progression vs Men: A Systematic Review and Meta-analysis.

BACKGROUND & AIMS Risk of nonalcoholic fatty liver disease (NAFLD) and its progression may differ between men and women. We conducted a systematic review and meta-analysis to determine the relationship between sex and NAFLD, nonalcoholic steatohepatitis (NASH), and advanced NAFLD fibrosis METHODS: Studies reporting sex-stratified NAFLD prevalence among population-based samples and either NASH or advanced fibrosis among patients with biopsy-proven NAFLD were identified from MEDLINE, EMBASE, and Cochrane databases through December 2017. We calculated pooled relative risk ratios comparing women vs men for each outcome. RESULTS Our final analysis comprised 54 studies. Samples sizes were 62,239 for the NAFLD analysis, 5428 for the NASH analysis, and 6444 for the advanced fibrosis analysis. Women had a 19% lower risk of NAFLD than men in the general population (pooled risk ratio [RR], 0.81; 95% CI, 0.68-0.97; I2, 97.5%). Women had a similar risk of NASH (RR, 1.00; 95% CI, 0.88-1.14; I2, 85.1%) and 37% higher risk of advanced fibrosis (RR, 1.37; 95% CI, 1.12-1.68; I2, 74.0%) than men. Age modified the effect of sex on NAFLD severity. Risks of NASH (RR, 1.17; 95% CI, 1.01-1.36) and advanced fibrosis (RR, 1.56; 95% CI, 1.36-1.80; I2=0) were substantially higher in women in study populations with average ages of 50 year or more; sex differences in NASH and advanced fibrosis were attenuated in younger populations. CONCLUSIONS In a systematic review and meta-analysis, we found women to have a lower risk of NAFLD than men. However, once NAFLD is established, women have a higher risk of advanced fibrosis than men-especially after age 50 years.

• Publication year

  2020

• Venue

  Clinical Gastroenterology and Hepatology

• Publication date

  2020-04-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.cgh.2020.04.067PMID 32360810PMCID PMC8796200
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Mechanisms of NAFLD development and therapeutic strategies

  2018cited by this paper
• The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

  2018cited by this paper
• Metabolic syndrome and its components in premenopausal and postmenopausal women: a comprehensive systematic review and meta-analysis on observational studies

  2018cited by this paper
• Prevalence of Nonalcoholic Steatohepatitis-Associated Cirrhosis in the United States: An Analysis of National Health and Nutrition Examination Survey Data

  2017cited by this paper
• Blood lead level is associated with non-alcoholic fatty liver disease in the Yangtze River Delta region of China in the context of rapid urbanization

  2017cited by this paper
• Evaluation of non-invasive diagnostic methods as indicators of fibrosis in patients with nonalcoholic fatty liver disease

  2017cited by this paper
• Sarcopenia is associated with severe liver fibrosis in patients with non‐alcoholic fatty liver disease

  2017cited by this paper
• External validation of the non‐alcoholic fatty liver disease fibrosis score for assessing advanced fibrosis in Korean patients

  2017cited by this paper
• Nonalcoholic fatty liver disease in adolescents and young adults: The next frontier in the epidemic

  2017cited by this paper
• The Association Between Nonalcoholic Fatty Liver Disease and Metabolic Abnormalities in The United States Population

  2017cited by this paper
• Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis.

  2017cited by this paper
• Racial and Ethnic Disparities in Nonalcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Systematic Review and Meta‐analysis

  2017cited by this paper
• Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

  2017cited by this paper
• Gender differences in liver disease and the drug‐dose gender gap

  2017cited by this paper
• Study quality assessment tools

  2016cited by this paper
• Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes

  2016cited by this paper
• Trends in the Burden of Nonalcoholic Fatty Liver Disease in a United States Cohort of Veterans.

  2016cited by this paper
• Prevalence of nonalcoholic fatty liver disease in an adult population in a rural community of Haryana, India

  2016cited by this paper
• Progression of Metabolic Syndrome Severity During the Menopausal Transition

  2016cited by this paper
• The development of a non‐invasive model to predict the presence of non‐alcoholic steatohepatitis in patients with non‐alcoholic fatty liver disease

  2016cited by this paper
• Gender impacts on the correlations between nonalcoholic fatty liver disease and hypertension in a Chinese population aged 45–60 y

  2016cited by this paper
• The Prevalence of Metabolic Syndrome In Non-alcoholic Fatty Liver Disease; A Population-Based Study

  2016cited by this paper
• Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006

  2015cited by this paper
• Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009

  2015cited by this paper
• Higher Estimated Net Endogenous Acid Production May Be Associated with Increased Prevalence of Nonalcoholic Fatty Liver Disease in Chinese Adults in Hong Kong

  2015cited by this paper
• Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.

  2015cited by this paper
• Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort.

  2015cited by this paper
• Nonalcoholic Fatty Liver: The Association with Metabolic Abnormalities, Body Mass Index and Central Obesity—A Population-Based Study

  2015cited by this paper
• Relationship between hemoglobin levels and risk for suspected non-alcoholic fatty liver in Taiwanese adults.

  2014cited by this paper
• Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease.

  2014cited by this paper
• Type 2 diabetes mellitus is associated with the fibrosis severity in patients with nonalcoholic fatty liver disease in a large retrospective cohort of Japanese patients

  2014cited by this paper
• Prevalence of Non-Alcoholic Fatty Liver Disease and Its Predictors in North of Iran

  2014cited by this paper
• Coffee consumption in NAFLD patients with lower insulin resistance is associated with lower risk of severe fibrosis

  2014cited by this paper
• Nonalcoholic steatohepatitis in nonalcoholic fatty liver disease patients of Bangladesh.

  2013cited by this paper
• Predictors of All-Cause Mortality and Liver-Related Mortality in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

  2013cited by this paper
• Regional anthropometric measures associated with the severity of liver injury in patients with non‐alcoholic fatty liver disease

  2013cited by this paper
• Suboptimal performance of simple noninvasive tests for advanced fibrosis in Chinese patients with nonalcoholic fatty liver disease

  2012cited by this paper
• Nonalcoholic Fatty Liver Disease Is Associated With Atherosclerosis in Middle-Aged and Elderly Chinese

  2012cited by this paper
• Ethnicity and nonalcoholic fatty liver disease

  2012cited by this paper
• Impaired renal function in morbid obese patients with nonalcoholic fatty liver disease

  2012cited by this paper
• The BARD score and the NAFLD fibrosis score in the assessment of advanced liver fibrosis in nonalcoholic fatty liver disease

  2012cited by this paper
• Etiology and prevalence of abnormal serum alanine aminotransferase levels in a general population in Northeast China.

  2011cited by this paper
• Nonalcoholic steatohepatitis and increased risk of chronic kidney disease.

  2011cited by this paper
• Risk of nonalcoholic steatohepatitis and fibrosis in patients with nonalcoholic fatty liver disease and low visceral adiposity.

  2011cited by this paper
• Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

  2011cited by this paper
• Polychlorinated Biphenyls, Lead, and Mercury Are Associated with Liver Disease in American Adults: NHANES 2003–2004

  2010cited by this paper
• Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease

  2010cited by this paper
• The clinical utility of biomarkers and the nonalcoholic steatohepatitis CRN liver biopsy scoring system in patients with nonalcoholic fatty liver disease

  2009cited by this paper
• Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement

  2009cited by this paper
• Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.

  2009cited by this paper
• Triglyceride Levels and Not Adipokine Concentrations Are Closely Related to Severity of Nonalcoholic Fatty Liver Disease in an Obesity Surgery Cohort

  2009cited by this paper
• Independent predictors of fibrosis in patients with nonalcoholic fatty liver disease.

  2009cited by this paper
• Adipokine Serum Levels Are Related to Liver Histology in Severely Obese Patients Undergoing Bariatric Surgery

  2009cited by this paper
• Long-term follow-up of patients with nonalcoholic fatty liver.

  2009cited by this paper
• Non‐alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C‐reactive protein in Hispanics

  2009cited by this paper
• Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

  2008cited by this paper
• Genetic polymorphisms of adiponectin and tumor necrosis factor‐alpha and nonalcoholic fatty liver disease in Chinese people

  2008cited by this paper
• Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection.

  2007cited by this paper
• Clinicopathological study of nonalcoholic fatty liver disease in Japan: the risk factors for fibrosis

  2007cited by this paper
• Long term nutritional intake and the risk for non-alcoholic fatty liver disease (NAFLD): a population based study.

  2007cited by this paper
• Non‐alcoholic fatty liver disease in Malaysia: A demographic, anthropometric, metabolic and histological study

  2007influential reference
• The Prevalence of Nonalcoholic Steatohepatitis is Greater in Morbidly Obese Men Compared to Women

  2006cited by this paper
• Prevalence and Risk Factors of Nonalcoholic Fatty Liver Disease in an Adult Population of Taiwan: Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese Adults

  2006cited by this paper
• The characteristics and natural history of Japanese patients with nonalcoholic fatty liver disease.

  2005cited by this paper
• Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non‐alcoholic fatty liver disease

  2005cited by this paper
• Predictors of Nonalcoholic Steatohepatitis and Advanced Fibrosis in Morbidly Obese Patients

  2005cited by this paper
• Design and validation of a histological scoring system for nonalcoholic fatty liver disease

  2005cited by this paper
• Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease

  2005cited by this paper
• Should a liver biopsy be done in patients with subclinical chronically elevated transaminases?

  2004cited by this paper
• Clinical characteristics and prevalence of GB virus C, SEN virus, and HFE gene mutation in Japanese patients with nonalcoholic steatohepatitis

  2004cited by this paper
• Consensus Statement

  2004cited by this paper
• Factors Associated or Related to with Pathological Severity of Nonalcoholic Fatty Liver Disease

  2004cited by this paper
• Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity

  2004cited by this paper
• Progression of liver fibrosis in women infected with hepatitis C: Long‐term benefit of estrogen exposure

  2004cited by this paper
• Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes.

  2003cited by this paper
• Clinical course of hepatitis C virus during the first decade of infection: cohort study

  2002cited by this paper
• Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis.

  2001cited by this paper
• Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

  2001cited by this paper
• Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group.

  2000cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions

  1999cited by this paper
• Bias in meta-analysis detected by a simple, graphical test

  1997cited by this paper
• Drinking habits as cofactors of risk for alcohol induced liver damage

  1997cited by this paper

• Low anti-Mullerian hormone in reproductive age is associated with MASLD in midlife.

  2026cites this paper
• Understanding liver and digestive diseases: a paved road to improve diagnosis, management, and treatment

  2026cites this paper
• Integrating body composition analysis and machine learning for non-invasive identification of metabolic dysfunction-associated fatty liver disease: a large-scale health examination-based study

  2026cites this paper
• DPP4 inhibition affects metabolism and inflammation associated pathways in hiPSC-derived steatotic HLCs

  2026cites this paper
• Diabetes and Obesity reduce FIB-4 accuracy in MASLD referral pathways

  2026cites this paper
• Gut-liver axis drives the triple mechanism of liver inflammation-carcinogenesis: Microbial-immune-metabolic network.

  2026cites this paper
• Biological determinants and outcomes of sex discrepancies in MASLD

  2026cites this paper
• The association between non-alcoholic fatty liver disease with blood selenium level based on the NHANES 2017–2020

  2026cites this paper
• Therapeutic Potential of Conyza bonariensis n‐Hexane Extract in Non‐Alcoholic Fatty Liver Disease: Histological, Biochemical, and In Silico Insights From a High‐Fat Diet Rat Model

  2025cites this paper
• Gut microbial conversion of dietary elderberry extract to hydrocinnamic acid improves obesity-associated metabolic disorders

  2025cites this paper
• Association of Kidney Stone Disease With Metabolic Dysfunction Associated Liver Disease and Metabolic Dysfunction Associated Steatohepatitis: A National Inpatient Sample Study

  2025cites this paper
• Association between waist circumference and fatty liver disease in older adult population: a cross-sectional study in Urumqi

  2025cites this paper
• The silent toll: understanding the complications of type 2 diabetes mellitus in the male body: a narrative review article

  2025cites this paper
• Body muscle mass versus fat mass: gender-specific associations with NAFLD and liver fibrosis

  2025cites this paper
• Serum uric acid trajectories and risk of metabolic dysfunction-associated steatotic liver disease in China: a 2019–2021 cohort health survey

  2025cites this paper
• Advancing precision medicine in metabolic dysfunction-associated steatotic liver disease.

  2025cites this paper
• Characteristics of serum bile acid profiles among individuals with metabolic dysfunction-associated steatotic liver disease

  2025cites this paper
• Sex‐dimorphic gene regulation in murine macrophages across niches

  2025cites this paper
• Sex differences in the prevalence and cardiometabolic risk profiles of steatotic liver disease: A Canadian Longitudinal Study on Aging analysis.

  2025cites this paper
• Sex‐Specific Impact of Metabolic Dysfunction‐Associated Fatty Liver Disease on Incident Cardiovascular Diseases and Mortality

  2025cites this paper
• Widening research horizons on metabolic dysfunction-associated steatotic liver disease and cancer.

  2025cites this paper
• "Diagnosis Frequency and Associated Factors of Non-Alcoholic Fatty Liver Disease among U.S Hospitalized Adults in Urban vs. Rural populations from 2007 - 2019: An Emerging Public Health Crisis".

  2025cites this paper
• Sex and gender differences in MASLD: pathophysiological mechanisms, clinical implications, and future directions

  2025cites this paper
• Advances in the treatment of hepatocellular carcinoma: An overview of the current and evolving therapeutic landscape for clinicians

  2025cites this paper
• Metabolic dysfunction‐associated steatotic liver disease and sex‐specific risk of fatal and non‐fatal cardiovascular events: A meta‐analysis

  2025cites this paper
• Global, regional and national burden of Metabolic dysfunction-associated steatotic liver disease in adolescents and adults aged 15–49 years from 1990 to 2021: results from the 2021 Global Burden of Disease study

  2025cites this paper
• Inter- and intra-observer agreement in ultrasound diagnosis of steatotic liver disease: implications for screening in resource-limited settings

  2025cites this paper
• Orexin-A Levels in Non-Alcoholic Fatty Liver Disease: A Case- Control Study Exploring Metabolic and Hepatic Correlations

  2025cites this paper
• β-Caryophyllene Ameliorates Thioacetamide-Induced Liver Fibrosis in Rats: A Preventative Approach

  2025cites this paper
• Pimpinella thellungiana ameliorates liver damage in osteoporotic rats based on metabolomics and network pharmacology.

  2025cites this paper
• Gender Differences in Healthy Eating Index as Informed by the Awareness of Diagnosis of Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• Fatty Liver Index Increases the Risk of Sudden Cardiac Arrest in Cardiovascular Disease-Free Adults.

  2025cites this paper
• Cirrhosis incidence across socioeconomic and demographic groups in Sweden: a register-based cohort study.

  2025cites this paper
• Human genetics of steatotic liver disease: insights into insulin resistance and lipid metabolism

  2025cites this paper
• Posicionamento sobre a Saúde Cardiometabólica ao Longo do Ciclo de Vida da Mulher – 2025

  2025cites this paper
• Position Statement on Cardiometabolic Health Across the Woman's Life Course – 2025

  2025cites this paper
• Relationship between serum uric acid levels and metabolism associated fatty liver disease in postmenopausal women based on NHANES 2017–2020

  2025cites this paper
• Impact of thyroid dysfunction and diabetes on fibrosis and steatosis stages in metabolic dysfunction associated fatty liver disease

  2025influential citation
• Impact of the Underutilization of Vibration-Controlled Transient Elastography in MASLD Patients Without Insurance Coverage

  2025cites this paper
• Effects of long working hours on metabolic dysfunction-associated steatotic liver disease, with and without increased alcohol intake, in healthy workers: A 10-year cohort study

  2025cites this paper
• MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women

  2025cites this paper
• Possible Role of Platelets in the Development and Progression of Non-Alcoholic Fatty Liver Disease.

  2025cites this paper
• Hypertension associated with the risk of extrahepatic cancers in MASLD population: a multicenter cross-sectional study in China

  2025cites this paper
• Ancestral bisphenol A exposure led to non-alcoholic fatty liver disease and sex-specific alterations in proline and bile metabolism pathways in the liver.

  2025influential citation
• Association of liver fibrosis−4 index with functional outcomes in chinese patients with acute ischemic stroke undergoing mechanical thrombectomy

  2025cites this paper
• The relationship between dietary sodium intake and all-cause mortality in patients with non-alcoholic fatty liver disease: a cohort study from NHANES 2003–2018

  2025cites this paper
• Prevalence of MASLD and Fibrosis Risk in Turkish Adults with Cardiometabolic Risk Factors: A Nationwide Multicenter Study (DAHUDER MASLD Study)

  2025cites this paper
• Low HDL cholesterol levels in women and hypertriglyceridemia in men: predictors of MASLD onset in individuals without steatosis

  2025cites this paper
• Representation of Sex, Race and Ethnicity in MASH Randomised Controlled Trials: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Racial and Ethnic Disparities in NAFLD: Harnessing Epigenetic and Gut Microbiota Pathways for Targeted Therapeutic Approaches

  2025cites this paper
• Serum Mac-2 binding protein glycosylation isomer as a biomarker for metabolic dysfunction associated steatotic liver disease

  2025cites this paper
• Association between metabolic-associated fatty liver disease and risk of cardiometabolic multimorbidity: a disease trajectory analysis in UK Biobank

  2025cites this paper
• HCC in MASLD and ALD: Biochemical Pathways, Epidemiology, Diagnosis, and Treatment

  2025cites this paper
• Prevalence of Hepatic Steatosis and Fibrosis in Asian Indian Individuals with Type 2 Diabetes

  2025cites this paper
• Liver-Kidney-Metabolic Health, Sex, and Menopause Impact Total Scores and Monovessel vs. Multivessel Coronary Artery Calcification

  2025cites this paper
• Mediation Analysis of the Molecular Phenotypes in a Severe MASH-like Liver Injury Mouse Model.

  2025cites this paper
• Identification of foam cell like M2 macrophages, AEBP1 biomarkers, and resveratrol as potential therapeutic in MASLD using Ecotyper and WGCNA

  2025cites this paper
• Facial Appearance and Markers of Cardiometabolic Risk in Healthy Adult Men

  2025cites this paper
• DECODING THE RISK PROFILE OF NON-ALCOHOLIC FATTY LIVER DISEASE: A SYSTEMATIC REVIEW AND META-ANALYSIS

  2025cites this paper
• Correspondence to editorial on “GOLM1 promotes cholesterol gallstone formation via ABCG5-mediated cholesterol efflux in MASH livers”

  2025cites this paper
• Influence of Sex in the Development of Liver Diseases

  2025cites this paper
• Plasma Hepatic Transaminases and Incidence of Metabolic Syndrome Before Midlife in Military Adults: A CHIEF Cohort Study

  2025cites this paper
• Sex-specific mechanisms in the pathogenesis and progression of chronic kidney disease.

  2025cites this paper
• Liver Fibrosis and Risk of Incident Dementia in the General Population: Systematic Review With Meta‐Analysis

  2025cites this paper
• Sex Differences in MASLD After Age 50: Presentation, Diagnosis, and Clinical Implications

  2025influential citation
• Sex Hormones and Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• Hepatic HKDC1 deletion alleviates western diet-induced MASH in mice.

  2025cites this paper
• Relationship between MASLD and women’s health: A review

  2025cites this paper
• Stable Transmission of DNA Methylation Epimutations from Germlines to the Liver and Their Association with Fatty Liver Disease in Medaka

  2025cites this paper
• The diet-derived gut microbial metabolite 3-phenylpropionic acid reverses insulin resistance and obesity-associated metabolic dysfunction

  2025cites this paper
• Disparities in Health Care in Patients With Chronic Liver Disease.

  2025cites this paper
• Differential candidate characteristics associated with increasing ALD and MASH among liver transplant listings in the US.

  2025cites this paper
• Sex differences in predicting dyslipidemia using polygenic risk score with fatty liver index and fibrotic nonalcoholic steatohepatitis index

  2025cites this paper
• Sex differences in alcohol-related liver disease, viral hepatitis, metabolic dysfunction-associated steatotic liver disease, and hepatocellular carcinoma

  2025cites this paper
• The Value of TyG-Related Indices in Evaluating MASLD and Significant Liver Fibrosis in MASLD

  2025cites this paper
• Association between oxidative stress and liver fibrosis severity in non-alcoholic fatty liver disease: insights from the pro-oxidant antioxidant balance method in a population from Tehran and Mashhad, Iran

  2025cites this paper
• Sex differences in diet-induced MASLD – are female mice naturally protected?

  2025cites this paper
• Modulation of Gut Microbes and Hepatic Metabolites by PCP Ameliorates NASH and Fatigue-like Performance in Mice

  2025cites this paper
• The importance of sex dimorphism in liver metabolism and progressive liver diseases

  2025cites this paper
• Metabolism, sex, and what lies beyond the scalpel in MASLD

  2025cites this paper
• MAFLD vs. MASLD: a year in review

  2025cites this paper
• Prevalence and associated factors of MAFLD in adults with type 2 diabetes

  2024cites this paper
• Hepatic HKDC1 Deletion Alleviates Western Diet-Induced MASH in Mice

  2024cites this paper
• Endpoints in NASH Clinical Trials: Are We Blind in One Eye?

  2024influential citation
• Contribution of Sex Differences to the Development of Cardiovascular Disease in Metabolic-Associated Steatotic Liver Disease (MASLD)

  2024cites this paper
• A LITERARY REVIEW OF NON-ALCOHOLIC FATTY LIVER DISEASE W.S.R. SANTARPANAJANYA VYADHI

  2024cites this paper
• Sex and Gender Differences in Liver Fibrosis: Pathomechanisms and Clinical Outcomes

  2024cites this paper
• Prognostic Characteristics of Metabolic Dysfunction-Associated Steatotic Liver in Patients with Obesity Who Undergo One Anastomosis Gastric Bypass Surgery: A Secondary Analysis of Randomized Controlled Trial Data

  2024cites this paper
• Liver-specific actions of GH and IGF1 that protect against MASLD

  2024cites this paper
• Diagnostic and prognostic value of plasma lipocalin-2 levels in patients with metabolic dysfunction–associated steatotic liver disease

  2024cites this paper
• Depression and the risk of non-alcohol fatty liver disease: Results from a cross-sectional study and a Mendelian randomization analysis.

  2024cites this paper
• Sex differences in murine MASH induced by a fructose-palmitate-cholesterol-enriched diet

  2024cites this paper
• Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease

  2024cites this paper
• Dietary Nutritional Supplements Are Associated with the Deterioration of Hepatic Fibrosis in Women and Individuals without Underlying Disease

  2024cites this paper
• Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries.

  2024cites this paper
• Estrogen: the forgotten player in metaflammation

  2024cites this paper
• The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.

  2024cites this paper
• Association of fatty liver index with sudden cardiac arrest in young adults.

  2024cites this paper
• A preclinical model of severe NASH-like liver injury by chronic administration of a high-fat and high-sucrose diet in mice.

  2024cites this paper
• Gut Microbes, Diet, and Genetics as Drivers of Metabolic Liver Disease: A Narrative Review Outlining Implications for Precision Medicine.

  2024cites this paper